Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/carboplatin plus maintenance letrozole versus letrozole alone for primary low-grade serous ovarian or peritoneal carcinoma
2024-516530-36-00Phase 3Authorised
- Sponsor
- Cancer Trials Ireland
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in Serous Papillary Cystadenocarcinoma, low-grade serous peritoneal adenocarcinoma and fallopian tube serous adenocarcinoma (FTC) comparing Paclitaxel + carboplatin followed by maintenance letrozole with Letrozole monotherapy (2 arms). Primary endpoints: Progression-free survival, Interim analysis for futility and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
letrozolepaclitaxelcarboplatin
03
Conditions
Serous Papillary Cystadenocarcinomalow-grade serous peritoneal adenocarcinomafallopian tube serous adenocarcinoma (FTC)
Beyond the preview
Go deeper on 2024-516530-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516530-36-00.